• Jędrzej Dragan, Jagoda Kania, and Maciej Salagierski.
• Urology Department, Faculty of Medicine and Health Sciences, University of Zielona Gora, Zielona Gora, Poland.
• Arch Med Sci. 2021 Jan 1; 17 (3): 805-811.

AbstractProstate cancer (PCa) is the most common cancer in men, with a steadily rising incidence, affecting on average one in six men during their lifetime. The increase in morbidity is related to the increasing overall life expectancy, prostate-specific antigen testing, implementation of new molecular markers for cancer detection and the more frequent application of multiparametric magnetic resonance imaging. There is growing evidence demonstrating that active surveillance (AS) is an alternative to immediate intervention in patients with very low- and low-risk prostate cancer. Ongoing reports from multiple studies have consistently demonstrated a very low rate of metastases and prostate cancer specific mortality in selected cohorts of patients. As a matter of fact, AS has been adopted by many institutions as a safe and effective management strategy. The aim of our review is to summarize the contemporary data on AS in patients affected with PCa with the intention to present the most clinically useful and pertinent AS protocols.Copyright: © 2020 Termedia & Banach.

4 keywords...

hide…